25.88 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||25.92 x 1000|
|Ask||25.96 x 1200|
|Day's Range||24.58 - 26.68|
|52 Week Range||15.12 - 45.68|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.75|
Third quarter Total Revenue of $46.7 million, up 148% year-over-year207,815 enrolled Livongo for Diabetes Members, up 118% year-over-year2019 revenue guidance range raised to.
The S&P 500 closed at an all time high on Monday evening -- then closed at an even higher high on Wednesday -- 3,046.77. Goldman Sachs believes this rally could keep going well into 2020.A recent report from Goldman Sachs predicts that 2020 will see corporations spend nearly a half-trillion dollars on stock buybacks, mergers, and acquisitions next year. Add in buying by U.S. individual investors and foreign investors, and that buying could be pushed well beyond the $500 billion-mark, says Goldman Sachs analyst David Kostin, as investors seek to profit from "positive equity market returns," buoyed by "rising interest rates, and stabilizing US and World GDP growth."But where do you look to find those profits specifically?Using the Stock Screener at TipRanks to seek out highly rated stocks in the ever-growing healthcare sector, for which Goldman Sachs analysts expect to see double, near double, or more than double returns in the next 12 months, we've come up with three candidates for you today.Arvinas Holding (ARVN)Based in New Haven, Connecticut, cancer-fighter Arvinas is researching therapies to degrade cancer-causing proteins in diseases such as prostate cancer and breast cancer.Goldman Sachs analyst Terence Flynn upgraded Arvinas to "buy" with a $38 price target after reviewing the result of Phase 1 clinical trials of the company's ARV-110 (for prostate cancer) and ARV-471 (for breast cancer) drugs. (To watch Flynn's track record, click here)As the label "Phase 1" suggests, Flynn admits that "trials are still in the early stages," but initial safety data looks good, opening a path to proceed to evaluating "first clinical efficacy data." Flynn increases his probability of success for both ARV-110 and ARV-471 to 25% (vs. 20% prior) given the initial safety/PK data presented, which in his view "provide some incremental de-risking of the drugs."If all goes well, Flynn foresees "blockbuster potential" for both drugs, with potential peak sales of $2.9 billion and $4.7 billion, respectively -- a big improvement over the $15 million in revenue Arvinas has booked over the last 12 months.Street sentiment on this one is good as well, with three analysts initiating coverage of Arvinas over the last three months -- in addition to Goldman's upgrade. And like Goldman, all three of these other analysts rate the stock a "buy," which qualifies the stock for "strong buy" sentiment in our book. A consensus target price of $38 (in line with Goldman's own target price) implies 81% upside for the shares over the next 12 months. (See Arvinas stock analysis on TipRanks)Livongo Health (LVGO)Next up: taking a different path to healthcare, Livongo Health is a Mountain View, California, software company seeking to harness data to improve patient outcomes in the fields of hypertension treatment, diabetes care, and weight management.This one attracted the attention of Goldman Sachs analyst Robert Jones, after Livongo was awarded a contract "to provide the Livongo for Diabetes solution to eligible members covered by the Federal Employees Health Benefits program under one health plan covering 5.3mn lives." Beginning on January 1, 2020, and for at least nine to 12 months thereafter, Livongo will work to reduce diabetes in the federal workforce -- and receive between $20 million and $25 million for its services in 2020, and perhaps $30 million to $35 million in 2021 if all goes well.This single contract, therefore, holds the potential to grow Livongo's $113 million in trailing revenues by 22% next year -- and push Livongo stock up as high as $43 a share, in Jones' estimation, over the next 12 months.The rest of Wall Street is even more optimistic. More than half a dozen analysts have chimed in over the past couple of months, most with buy ratings, and with an average price target of $43.63. If they're right, that means Livongo stock could more than double over the next 12 months. (See Livongo stock analysis on TipRanks)Myovant Sciences (MYOV) Returning to the pharmaceutical field now, but shifting our gaze to the UK, London-based Myovant Sciences is a clinical-stage biopharmaceutical company working to develop drugs for use in women's health, with backing from Japan's Sumitomo Dainippon Pharma, which took a 46% stake in the company last quarter and is helping to move Myovant towards commercial production.Goldman Sachs analyst Paul Choi isn't looking for earnings to be much of a catalyst for the stock (because there are none). But sales revenue is anticipated to begin rolling in next year, and could quadruple to more than $153 million by 2021. Furthermore, Choi recommends the stock in anticipation of the companies signing a "definitive agreement" of their partnership, assigning Myovant stock a "buy" rating and an $18 price target. (To watch Choi's track record, click here)Wall Street as a whole is similarly bullish, with three "buy" ratings filed in the last two months (including Goldman's), making the stock a "Strong Buy" according to TipRanks. With Street analysts positing an average $22 average price target, Myovant shows the most profit potential of all on today's list -- 325% to be exact. (See Myovant stock analysis on TipRanks)
MOUNTAIN VIEW, Calif., Oct. 31, 2019 -- Livongo Health, Inc., (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better.
Livongo Health, Inc. (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced at the HLTH 2019 Conference being held in Las Vegas, Nevada, that it has teamed with MDLIVE and Doctor On Demand to enable access to virtual acute and primary care services for people living with chronic conditions. Livongo will enable access to telehealth services for Livongo Members, beginning with Livongo for Behavioral Health, effective January 2020, and soon expanding to Livongo’s diabetes and hypertension offerings.
Livongo Health, Inc. (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced that it has expanded its partnership with Blue Cross and Blue Shield of Kansas City (Blue KC) to offer the Livongo for Diabetes program to all Blue KC fully insured clients. In addition, Livongo is now available to eligible Blue KC Administrative Services Only (ASO) clients. To date, Blue KC clients using Livongo demonstrated a combined +75 NPS score and a significant decrease in eHbA1c.
Livongo Health, Inc., a leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced a partnership with VSP® Vision Care to expand outreach efforts to Members with diabetes. This partnership includes the opportunity for mutual clients to provide their employees with important reminders to schedule their annual comprehensive eye exam with a VSP network doctor.
Livongo Health, Inc., (Nasdaq: LVGO) today announced it will hold a conference call on Wednesday, November 6, 2019, after close of U.S. stock market at 4:30 p.m. Eastern Time to discuss results for third quarter ended September 30, 2019. Livongo offers a whole person platform that empowers people with chronic conditions to live better and healthier lives, beginning with diabetes and now including hypertension, weight management, pre-diabetes, and behavioral health. The Livongo approach has demonstrated that it can deliver better clinical and financial outcomes while creating a different and better experience for people with chronic conditions.
MOUNTAIN VIEW, Calif., Oct. 14, 2019 -- Livongo Health, Inc., (Nasdaq: LVGO) today announced the Company will be participating in the Credit Suisse 28th Annual Healthcare.
PHILADELPHIA, PA / ACCESSWIRE / October 8, 2019 / Kaskela Law LLC is investigating Livongo Health, Inc. ("Livongo" or the "Company") (NASDAQ:LVGO) on behalf of investors. The investigation ...
Livongo Health soars Monday after raising its outlook for its diabetes members program as a result of being awarded a contract by the Federal Employees Health Benefits Program.
Shares of Livongo Health Inc. soared 8.5% in premarket trading Monday, after the diabetes treatment company raised its outlook for its diabetes members program, after it was awarded a contract by the Federal Employees Health Benefits Program (FEHBP). The company said it signed a two-year agreement which will launch the "Livongo for Diabetes" program on Jan. 1, 2020, which it expects will add about 25,000 members in 2020 and 45,000 members in 2021. The company had previously expected 20,000 to 30,000 members. Livongo expects the agreement to account for $20 million to $25 million in revenue in 2020 and $30 million to $35 million in revenue in 2021. Livongo went public on July 25 after its initial public offering priced at $28. The stock closed Friday at $17.32, or 38% below its IPO price. In comparison, the Renaissance IPO ETF has lost 13% since July 25 and the S&P 500 has slipped 1.7%.
MOUNTAIN VIEW, Calif., Oct. 07, 2019 -- Livongo Health, Inc (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better.
Shares of Livongo Health Inc. rose 1% in premarket trading Thursday, after the digital health company reported its first quarterly results since going public, with a wider-than-expected loss but revenue that rose above forecasts. The net loss widened to $14.3 million, or 76 cents a share, from $6.2 million, or 38 cents a share, in the year-ago period. Excluding non-recurring items, the adjusted loss per share was 46 cents, compared with the FactSet per-share loss consensus of 15 cents. Revenue rose 156% to $40.9 million, above the FactSet consensus of $39.7 million. Enrollment for Diabetes Members grew 140% to 192,934, while clients increased 92% to 720. For the third quarter, Livongo expects revenue of $42 million to $43 million, surrounding the FactSet consensus of $42.3 million. The stock has lost 19% since it closed at $38.10 on its first day of trading on July 25, while the S&P 500 has declined 2.2% over the same time.
Shares of healthcare industry solutions provider Livongo Health were rising in premarket trading Thursday after the company reported a second-quarter loss narrower than analysts' expectations. The Mountain View, California-based company reported a 156% increase in year-over-year revenue to $40.
Shares of Livongo Health Inc (NASDAQ: LVGO ) have lost nearly 20% since its late July IPO , and investors should take advantage of the discount valuation, according to Morgan Stanley. The Analyst Ricky ...
MOUNTAIN VIEW, Calif., Aug. 27, 2019 -- Livongo Health, Inc. (Nasdaq: LVGO), a leading Applied Health Signals company empowering people with chronic conditions to live better.
Today, Livongo announced that Founder and Executive Chairman Glen Tullman will be honored with a Robert F. Kennedy Human Rights Ripple of Hope Award for his career focused on improving the safety, empathy, and efficiency of our healthcare system. The Ripple of Hope Award celebrates leaders of the international business, entertainment, and activist communities who have demonstrated a commitment to social change. Past honorees include President Barack Obama, Archbishop Desmond Tutu, Bono, George Clooney, and Robert F. Smith.
Livongo Health Inc (NASDAQ: LVGO) shares have bumped up more than 30% since the company went public at the end of July, raising interest in the digital health platform company. KeyBanc Capital Market's Donald Hooker initiated coverage of Livongo Health with an Overweight rating and $46 price target. Livongo uses technology to manage chronic disease treatment, mostly in patients with diabetes, and both analysts said the company’s business model appear to give it a long growth runway.
MOUNTAIN VIEW, Calif., Aug. 07, 2019 -- Livongo Health, Inc. (Nasdaq: LVGO) today announced it will hold a conference call on Thursday, September 5, 2019 at 8:00 a.m. Eastern.
MOUNTAIN VIEW, Calif., July 29, 2019 -- Livongo Health, Inc., (Nasdaq: LVGO) today announced the closing of its initial public offering of 14,590,050 shares of its common stock.
MOUNTAIN VIEW, Calif., July 24, 2019 -- Livongo Health, Inc. (Livongo) today announced the pricing of its initial public offering of 12,687,000 shares of its common stock at a.
Fortune's Sy Mukherjee interviews Livongo CEO Zane Burke and President Jennifer Schneider at NASDAQ Marketsite in Manhattan, NY.